Carcinogenesis, Prevention and Treatment of Colorectal Cancer – State-of-the-Art 2012

February 10 – 11, 2012
The Westin Grand Hotel
Munich, Germany

Jointly co-organized with the ICRCC

Program
12 credit hours (CME) have been awarded for the Falk Symposium 182 by the European Union of Medical Specialists (UEMS) - European Board of Gastroenterology (EBG).
The World Health Organization (WHO) reported more than 600,000 deaths due to colorectal cancer in 2008 worldwide. The majority of these cancers could be prevented by the wide use of existing knowledge on cancer prevention, established screening methods and the use of modern treatment modalities. Since most colorectal cancers develop from adenomatous polyps, most cancers could be prevented by screening colonoscopies.

The current understanding of carcinogenesis in colorectal cancer has led to improved diagnostic and therapeutic tools, which increase the probability of long-term survival of colorectal cancer. Major improvements have been achieved in endoscopy, surgery, chemotherapy and radio-oncology over the last years. Therefore, all colorectal cancer patients should be discussed in interdisciplinary tumor boards to determine the best individualized treatment plan, based on current knowledge in each clinical specialty.

The aim of this international symposium „Carcinogenesis, Prevention and Treatment of Colorectal Cancer – State of the Art 2012“ is to discuss the up-to-date colorectal cancer knowledge with basic and clinical researchers, general practitioners and colorectal cancer specialists in a wide interdisciplinary setting. We expect the participation of a high number of renowned experts from all over the world to increase our knowledge about colorectal cancer in regard to our all mission to prevent and cure cancer.

We would like to thank the Falk Foundation for the generous support and for the chance to organize such an extraordinary and important meeting in Munich. We are convinced that this International Falk Symposium 2012 will lead to a fruitful discussion about colorectal cancer and we would like to invite you all to participate and to benefit from our meeting in Munich. Welcome to Munich!

Helmut Friess, Munich  
Roland M. Schmid, Munich  
Michael Fried, Zurich  
Cornelis van de Velde, Leiden
Carcinogenesis, Prevention and Treatment of Colorectal Cancer – State of the Art 2012

The Westin Grand Hotel
Munich, Germany

Registration:
Thursday, February 9, 2012
8.00 – 18.10 h
at the congress office

Jointly co-organized with the ICRCC

Scientific Organization:
H. Friess, Munich (Germany)
R. M. Schmid, Munich (Germany)
M. Fried, Zurich (Switzerland)
C. J. H. van de Velde, Leiden (The Netherlands)

Congress Secretary:
R. Rosenberg, Baden (Switzerland)
F. G. Bader, Munich (Germany)
S. von Delius, Munich (Germany)

Congress Venue:
The Westin Grand Hotel
Arabellastr. 6
81925 Munich
Germany

Information:
Prof. Dr. Helmut Friess
Department of Surgery
Klinikum rechts der Isar
Technische Universität München
Ismaninger Str. 22
81675 München
Germany
Telephone: +49(0)89/4140 21 21
Telefax: +49(0)89/4140 48 70
E-mail: colon2012@chir.med.tu-muenchen.de

Official Language:
English

Posters:
For details see page 11
8.30 Opening remarks

**Session I**

**Histopathological work-up, carcinogenesis and tumor dissemination**

*Chair: H. Höfler, Munich; A. Perren, Berne*

8.40 **State-of-the-Art Lecture**

Histopathological work-up of biopsies, local excisions and resection specimens in colorectal cancer

P. Quirke, Leeds

9.05 Molecular pathological pathways in the development of colorectal cancer

T. Kirchner, Munich

9.30 Mechanism of dissemination and metastases

C. A. Klein, Regensburg

9.55 MicroRNAs and inflammatory cytokines are associated with diagnosis, prognosis and therapeutic outcome of colon cancer

C. C. Harris, Bethesda

10.20 Coffee break with poster session

**Session II**

**From bench to bed – Molecular markers for clinical use**

*Chair: F. R. Greten, Munich; K.-P. Janssen, Munich; U. J. Roblick, Lübeck*

10.50 Molecular, blood and stool tests: ready to replace colonoscopy?

T. F. Imperiale, Indianapolis

11.15 Genetic and epigenetic mutations and targeted therapies in colon cancer – Have we made progress?

S. Tejpar, Leuven

11.40 Towards personalization in colon cancer – The impact of gene signatures and MSI status

D. J. Kerr, Oxford

12.10 Lunch break with poster session
Friday, February 10, 2012

Session III
Screening- and surveillance programs in low/high risk patients

**Chair:** M. Fried, Zurich; B. Göke, Munich

13.10 Colorectal cancer screening: Practice guidelines  
D. A. Lieberman, Portland

13.35 Hereditary colorectal cancer: Identification, surveillance and therapy strategies  
J. Burn, Newcastle

14.00 Inflammatory bowel disease: Cancer risk, detection and surveillance  
G. Rogler, Zurich

14.25 Chemoprevention of colorectal cancer with 5-ASA  
H. Herfarth, Chapel Hill

14.50 **Coffee break with poster session**

Session IV
Screening modalities, endoscopic adenoma detection and therapy

**Chair:** M. F. Neurath, Erlangen; R. M. Schmid, Munich

15.20 CT and MR colonography – Challenge for endoscopy  
D. C. Rockey, Dallas

15.45 Endoscopic detection of colorectal adenomas: Standards and sophisticated methods  
M. Anders, T. Rösch, Hamburg

16.10 Mucosectomy in the colorectum  
B. Saunders, London
Friday, February 10, 2012

Session V
Video session – State-of-the-Art colorectal and liver procedures

Chair: H. Friess, Munich; M. Ghadimi, Göttingen; E. Tiret, Paris

16.35 Complete mesocolic excision K. Weber, W. Hohenberger, Erlangen
17.00 Laparoscopic surgery for lower rectal cancer E. Rullier, Bordeaux
17.25 The Holm’ abdominoperineal resection G. Jansson-Palmer, T. Holm, Stockholm
17.50 Accelerated staged hepatectomy (ASH) for liver tumors P. A. Clavien, Zurich

18.15 End of afternoon session
Saturday, February 11, 2012

Session VI
Polypectomy and tailored surgery

**Chair:** M. Classen, Reith; C. A. Maurer, Liestal; H. Neuhaus, Düsseldorf

**8.30** The “difficult” polyp – Pitfalls for endoscopic removal  
M. Jung, Mainz

**8.55** Endoscopic therapy options for T1 colon and rectal cancer  
A. Meining, Munich

**9.20** Combined endoscopic-laparoscopic resection  
D. Hahnloser, Lausanne

**9.55** The TEM procedure – Standards and extended indications  
A. Kartheuser, Brussels

**10.20** Coffee break with poster session

Session VII
Management of non-metastatic colorectal cancer (stage I-III)

**Chair:** H. J. Buhr, Berlin; K.-W. Jauch, Munich; K.-H. Link, Wiesbaden

**10.50** Colorectal surgery – What is evidence-based and how should we do it?  
E. Tiret, Paris

**11.15** Bowel obstruction in stenotic colorectal cancer – Stent, stoma or primary resection  
P. B. Paty, New York

**11.40** Sphincter-saving surgery and reconstruction techniques – What is reasonable in the context of cure and functional results?  
A. D’Hoore, Leuven

**12.05** Multivisceral resection for T4 or recurrent colorectal cancer  
P. R. O’Connell, Dublin

**12.30** Adjuvant therapy of colon cancer – Present guidelines and future perspectives  
W. Schmiegel, Bochum

**12.55** Lunch break with poster session
Session VIII
Multimodal therapy in stage II / III rectal cancer
Chair: M. Molls, Munich; C. J. H. van de Velde, Leiden; S. D. Wexner, Weston

14.00 Neoadjuvant short- or long-term radio-(chemo)therapy: How and who should be treated? C. Rödel, Frankfurt

14.25 Specimen evaluation and histopathologic prognosticators after neoadjuvant therapy in rectal cancer M. Berho, Weston

14.45 Complete response after neoadjuvant therapy in rectal cancer: To operate or not to operate? S. D. Wexner, Weston

15.05 Which patient does not need a preoperative radiation? M. Büchler, Heidelberg

15.30 Quality assurance in rectal cancer treatment C. J. H. van de Velde, Leiden

15.55 Presentation of poster prizes
Chair: B. Bashankaev, Moscow; D. Kandioler, Vienna; A. Nissan, Jerusalem

16.10 Coffee break with poster session

Session IX
Management of patients with stage IV colorectal cancer
Chair: C.-T. Germer, Würzburg; A. Tuchmann, Vienna; M. Fried, Zurich

16.40 Synchronous resectable colorectal liver metastases B. Nordlinger, Boulogne

17.05 Oncological management of irresectable liver metastases E. van Cutsem, Leuven

17.30 Surgical results after downstaging of initially marginal or non-resectable liver metastases J. Belghiti, Paris

17.55 Hyperthermic intraperitoneal chemoperfusion HIPEC in peritoneal carcinomatosis R. Salazar, Barcelona

18.20 End of meeting
Poster Session

Posters will be exhibited on February 10 - 11, 2012, at the Westin Grand Hotel in Munich. The authors will be in attendance during coffee and lunch breaks on both days.

Poster Jury

B. Bashankaev, Moscow; A. Bembenek, Hannover; D. Kandolier, Vienna; M. E. Kreis, Munich; A. Nissan, Jerusalem; C. T. Viehl, Basel

1. The sphincter’s fate in low lying rectum cancer: A decision analysis
   M. Adamina, S. Wolf, B. Hummel, F. Näf, S. Bischofberger, T. Steffen (St. Gallen, CH)

2. Results of intraoperative pelvic hyperthermic chemotherapy for treatment of locally advanced rectal carcinoma
   M. Alekseev, E. Rybakov (Moscow, RU)

3. Extranodal non-Hodgkin’s lymphomas of gastrointestinal tract
   D. Badea, M. Badea, A. Genunche-Dumitrescu (Craiova, RO)

4. Incidence and clinical evolution of non-Hodgkin lymphoma (NHL) of the colon
   M. Badea, D. Badea, A. Genunche-Dumitrescu, L. Stefan, A. Badea, D. Duta (Craiova, RO)

5. The Ann Arbor Staging system versus modified Blackledge Staging system and Musoff system in the gastrointestinal lymphoma
   M. Badea, D. Badea, A. Genunche-Dumitrescu, C. Petrica, D. Iordache, L. Stefan, D. Duta, A. Badea (Craiova, RO)

6. Capnography improves patient safety during propofol sedation for colonoscopy: A randomized, controlled study (ColoCap Study)

7. Are there other indicators of quality of colonoscopy than adenoma detection rate (ADR)?
   M. Benes, P. Drastich, T. Hucl, P. Stirand, P. Wohl, J. Spicak (Prague, CZ)

8. Quality of endoscopic mucosal resection (EMR) at IKEM
   M. Benes, P. Drastich, P. Stirand, P. Wohl, T. Hucl, J. Spicak (Prague, CZ)
9. Compartimental differences of circulating tumor cells in colorectal cancer
   U. Bork, N.N. Rahbari, A. Kircher, E. Seyfarth, T. Niemetz, S. Schölch, C. Kahlert,
   M.W. Büchler, M. Koch, J. Weitz (Heidelberg, DE)

10. Non-invasive screening for colorectal cancer and colon adenomas
    S. Chernyshov, E. Zenkina (Moscow, RU)

11. Is the prevalence of colorectal adenoma higher in patients with gastric neoplasm?

12. Gradual loss of functional gap junction within progression from colorectal
    adenoma to cancer – A shift from membranous CX32 and CX43 expression to
    cytoplasmic pattern during colorectal carcinogenesis
    R. Dereniewicz-Wincewicz, A. Wincewicz, L. Kanczuga-Koda, M. Koda,
    S. Sulkowski (Kielce, Bialystok, PL)

13. Tubulo-villous colorectal adenocarcinoma vs. mucin and signet-ring cell carcinoma
    – Is there a prognostic difference?
    (Munich, DE; Baden, CH)

14. High myeloperoxidase positive cell density in colorectal cancer is an independent
    favorable prognostic factor
    R. Droeser, C. Hirt, S. Epenberger-Castori, I. Zlobec, C. T. Viehl, D. Frey, R. Rosso,
    G. Iezzi, G. Sconochia, G. Spagnoli, M. Heberer, A. Lugli, L. Terracciano,
    D. Oertli (Basel, Lugano, Bern, CH; Rome, IT)

15. Postoperative outcome and long-term survival after laparoscopic assisted right
    hemicolecotomy during the learning curve: A case-matched analysis with open
    approach
    T. Dumitrascu, C. Vasilescu, V. Tomulescu, M. Ionescu, I. Popescu (Bucharest, RO)

16. Risk factors for adverse outcome of emergent colon cancer surgery
    S. Faes, A. Schnider, M. Weber (Baden, Zurich, CH)

17. Ulcerative colitis as a risk factor for colorectal cancer
    O.V. Fedorova, E. Fedulova, O. Tutina, O. Shumilova (Nizhny Novgorod, RU)

18. IBD: Cytoprotection for the prevention of colorectal cancer
    O.V. Fedorova, E. Fedulova, O. Tutina, O. Shumilova (Nizhny Novgorod, RU)

19. HER-2/neu immunoexpression in colorectal and gastric carcinomas
    O. Fratila, T. Ilias, M. Puscasiu, R.G. Mihaila (Oradea, Sibiu, RO)
20. Oct4, spliced variant OCT4B1, a novel marker for human colorectal cancer
M. Gazouli, G. Theodoropoulos, M. Roubelakis, A. Vaiopoulou, J. Papailiou,
N. Nikiteas, N.P. Anagnou (Athens, GR)

21. Assessment of the local recurrence rates of colorectal cancer after curative resection
A. Genunche-Dumitrescu, D. Badea, M. Badea, P. Mitrut, A. Badea (Craiova, RO)

22. The contribution of major etiologic factors to the risk of colorectal cancer
A. Genunche-Dumitrescu, D. Badea, M. Badea, P. Mitrut (Craiova, RO)

23. Correlation of prognosis and gene expression signatures in colorectal cancer
J. Gröne, L. Lee, J. Lauscher, H. J. Buhr (Berlin, DE)

24. Molecular biomarkers play a major role in the selection of treatment strategies in CRC
J. Gülden, A. Bogner, M. Joka, K.-W. Jauch, B. Mayer (Munich, DE)

25. A genetic mouse model to identify the role of the immune adapter protein MyD88 in colon cancer
A. Holtorf, M. Martini, B. Holzmann, K.-P. Janssen (Munich, DE)

26. Colorectal cancer assessment in a group of patients from the western part of Romania
T. Ilias, O. Fratila, D. Puscasu (Oradea, RO)

27. Inflammatory response related gene polymorphisms and colorectal cancer
G. Karamanolis, G. Theodoropoulos, M. Gazouli (Athens, GR)

28. Laparoscopic surgery for rectal cancer
S. Kathy, D. Tóth, Z. Kincses (Debrecen, HU)

29. CXC-chemokines as crucial immune mediators in colorectal carcinogenesis
L. Keller, D. Doll, C. Ochs, K.-P. Janssen (Munich, DE)

30. The risk factors of colorectal cancer operations
Z. Kincses, T. Csobán, S. Kathy, D. Tóth (Debrecen, HU)

31. Importance of the long-term surveillance of patients with ulcerative colitis considering the occurrence of dysplastic changes and colorectal carcinoma
M. Konecny, V. Prochazka, J. Ehrmann (Olomouc, CZ)

32. Identification of prognostic factors for long-term survival in stage IV colorectal cancer patients
B. Künzli, U. Nitsche, M. Maak, R. Gertler, G. Ceyhan, T. Schuster, C. Meyer-
zum-Büschenfelde, H. Friess, R. Rosenberg (Liestal, CH; Munich, DE)
33. Initial results of a randomized controlled trial comparing clinical and pathological downstaging of rectal cancer after preoperative short-course radiotherapy or conventional chemoradiotherapy with delayed surgery
T. Latkauskas, H. Pauzas, P. Lizdenis, Z. Saladzinskas, A. Tamelis, D. Pavalkis (Kaunas, LT)

34. Radiofrequency-assisted hepatic resections metastases of colorectal cancer
A. Lavrinenko, V. Kashnikov, E. Rybakov, Y.A. Shelygin (Moscow, RU)

35. Neural invasion is not a prognostic factor in colon cancer due to missing neuro-cancer cell affinity

36. Systematic review and meta-analysis on the effect of preoperative radio(chemo)therapy on long-term functional outcome in rectal cancer patients

37. Tumor targeting of gastrointestinal carcinomas with Shiga toxin B
M. Maak, U. Nitsche, L. Johannes, R. Rosenberg, H. Friess, K.-P. Janssen (Munich, DE; Paris, F; Baden, CH)

38. Colonoscopy screening markedly reduces the occurrence of colon carcinomas and carcinoma-related death
C. Manser, L. Bachmann, J. Brunner, F. Hunold, M. Fried, P. Bauerfeind, U.A. Marbet (Zürich, Glarus, Altdorf, CH)

39. Complex pathology analysis of colorectal cancer in children
N.S. Marenich, A.S. Tertychnyy, D.M. Konovalov, A.G. Talalaev (Moscow, RU)

40. Microsimulation of colorectal cancer screening
B. Misselwitz, C. Manser, L. Biedermann, A. Sonnenberg, P. Bauerfeind (Zürich, CH; Portland, US)

41. A novel mouse model of orthotopic metastatic colon cancer
O. Movadat, A. Wlodarski, N. Wittkopf, M.F. Neurath, C. Becker (Erlangen, Mainz, DE)

42. Immunohistochemical screening of hMLH1 and hMSH2 gene mutations in patients diagnosed with colorectal cancer and microsatellite instability suspicion
F. Muresan, R. Simescu, I. Domsa, R. Buiga, M. Cazacu (Cluj-Napoca, RO)
43. Epiregulin promotes growth of colitis-associated tumors  
C. Neufert, C. Becker, M. Waldner, I. Backert, M.F. Neurath (Erlangen, DE)

44. Prediction of prognosis is not improved by the 7th edition of the TNM classification for colorectal cancer  

45. Integrative marker analysis and risk assessment in stage II colon cancer  

46. Surgical site infection in diabetic patients after colorectal surgery  
S. Panidis, D. Paramythiotis, D. Panagiotou, E. Karamanlis, V.N. Papadopoulos, A. Michalopoulos, G. Basdanis (Thessaloniki, GR)

47. Results of salvage abdominoperineal resection after failed chemoradiation therapy for epidermoid anal canal carcinoma: Retrospective analysis at a single institution  

48. Gastrointestinal quality of life after laparoscopic-assisted sigmoidectomy for diverticular disease  
I. Pasternak, N. Wiedemann, G. Basilicata, G. Melcher (Uster, Liestal, CH)

49. Effect of preoperative radiochemotherapy on lymph node retrieval after resection of rectal cancer  
H. Pauzas, T. Latkauskas, P. Lizdenis, Z. Saladzinskas, A. Tamelis, D. Pavalkis (Kaunas, LT)

50. Microvessel density could be strong prognostic marker after radiotherapy in rectal cancer  
D. Pavalkis, S. Svagzdys, V. Lesauskaite, Z. Saladzinskas, A. Tamelis (Kaunas, LT)

51. Gasless transanal endosurgery and transanal excision of rectal cancer: Experience from a single center in Moscow  
I. Peresada, Y.A. Shelygin, S. Chernyshov (Moscow, RU)

52. Anal sphincter preservation in ultra low rectal cancer surgery – Suffering for the patient or chance to continue customary life?  
D. Pikunov, E. Rybakov (Moscow, RU)

53. Adrenal metastases of colorectal carcinomas  
C. Pitt, K. Peitgen (Bottrop, DE)
54. Lymph node yield after rectal resection in patients treated with neoadjuvant radiation: A systematic review and meta-analysis
   S. Pohle, P. Quentmeier, M. Loos, U. Nitsche, M. Maak, T. Schuster, R. Langer, H. Friess, T. Kocher, R. Rosenberg (Baden, CH; Munich, DE)

55. Preoperative chemoradiotherapy increases sphincter-sparing procedure rate for rectal carcinoma patients
   A. Rasulov, Y.A. Shelygin, S. Zhdankina, A. Boiko, I. Droshneva (Moscow, RU)

56. HLA class I expression in colorectal cancer; prognostic and predictive relevance
   M. Reimers, E. Zeestraten, S. Saadatmand, G. Liefers, C.J.H. van de Velde, P.J.K. Kuppen (Leiden, NL)

57. Groin metastases of anal carcinoma: Surgery or chemoradiation
   E. Rybakov, S. Chernyshov (Moscow, RU)

58. Primary mixed goblet cell carcinoid/-adenocarcinoma of the cecum with stenotic metastasis in the sigmoid presents as a rare cause of decompensated colon ileus with sigmoid stenosis
   A. Sahin, S. Tschuppert, A. Wodzynski, M. Trippel, S. Saravanja, A. Keerl, R. Rosenberg, T. Kocher (Baden, CH)

59. Quality of life after sphincter-preserving rectal cancer resections
   J. Scheele, M. Meier, D. Henne-Bruns, M. Kornmann (Ulm, DE)

60. Postoperative complications and risk factors in robotic surgery for rectal cancer
   O. Sgarbura, M. Eftimie, V. Tomulescu, I. Popescu (Bucharest, RO)

61. Screening of irregular bowel movement frequency as functional risk factor of colorectal cancer
   C. Shemerovskii (St. Petersburg, RU)

62. Specific activity of cyclindependent kinase 1 predicts the recurrence of stage II colon cancer

63. Colorectal cancer in the region with enormously high occurrence rate: The projection of screening program and clinical practice
64. The effect of a nationwide screening program on the diagnosis of colorectal cancer (CRC) in a region with an enormously high occurrence
J. Spicak, M. Benes, T. Hucl, P. Stirand, P. Drastich, O. Urban, V. Nosek (Prague, Ostrava, Jablonec nad Nisou, CZ)

65. Surgical reoperations in cases of postoperative sepsis subsequent to the surgical treatment of colorectal cancer
G. Statescu, A. Statescu, M. Carausu (Iasi, RO)

66. MMP-9 is a strong prognostic survival marker in rectal carcinoma
S. Svagzdys, V. Lesauskaite, Z. Saladzinskas, A. Tamelis, D. Pavalkis (Kaunas, LT)

67. N-acetylcysteine has a powerful dual effect of anti-inflammatory and antioxidant activities resulting in complete improvement of acetic acid induced colitis in rats

68. Prognostic value and prediction of the presence of KRAS mutation on the basis of combined pathology data of colorectal cancer
A.S. Tertychnyy, G. De Hertogh, X. Sagaert, K. Geboes (Moscow, RU; Leuven, BE)

69. Single direct suture of the perineal wound after cylindrical abdominoperineal extirpation of the rectum (Holm-procedure) – An alternative to a Mesh or flap technique
W. Thasler, M. E. Kreis (Munich, DE)

70. Association of caspase-8 and -9 gene polymorphisms and colorectal cancer susceptibility and prognosis
G. Theodoropoulos, M. Gazouli, A. Vaiopoulou, N. Nikiteas (Athens, GR)

71. Results of extralevator abdomino-perineal resections for rectal cancer (multicenter study)
P.V. Tsarkov, I.A. Nechay, D.A. Hubezov, V.V. Polovinkin, Y.M. Makeev, A.M. Karachun, I. Tulina, M.A. Danilov, I.S. Tsarkov (Moscow, St. Petersburg, Ryazan, Krasnodar, Balashikha, RU)

72. D3 lymph node dissection in right colon cancer: Too much or just enough?
P.V. Tsarkov, B. Bashankaev, A. Kravchenko, I. Tulina (Moscow, RU)

73. The effectiveness of the multidisciplinary approach in elective surgery of colorectal cancer in elderly patients.
P.V. Tsarkov, V.V. Nikoda, V.I. Stamov, D.R. Markar’yan, I. Tulina (Moscow, RU)
74. Pretherapeutic selection of the most promising drugs for the individual CRC patient using the functional Spheroid Microtumor Model
K. Weiler, L. Rava, C. Ludwig, M. Joka, K.-W. Jauch, I. Funke, B. Mayer (Munich, DE)

75. Erythropoietin receptor expression in colorectal cancer – Immunohistochemical and mRNA studies – In perspective of treatment with recombinant EPO in colorectal cancer-associated anemia
A. Wincewicz, C. Miller, C. Blau, U. Sulkowska, S. Sulkowski (Bialystok, PL; Seattle, US)

76. The role of capsule endoscopy in evaluating and managing small bowel disorders
E. Yoong, K. Padmakumar (Manchester, Bolton, GB)

77. Stomach and colon cancer diagnosis of vitamin B12 and folic acid levels

78. Local recurrence rate in rectal cancer
W. Zaglmair, H. Wundsam, K. Rohregger, G. Pressl, M. Aufschnaiter, K. Emmanuel (Linz, AT)

79. Individual CRC-tumour-ID by combining biomarker profiling and functional 3D drug testing
M. Zoller, J. Gülden, M. Joka, I. Funke, K.-W. Jauch, B. Mayer (Munich, DE)
List of Speakers, Moderators and Scientific Organizers

PD Dr. Mario Anders
Klinik und Poliklinik für Interdisziplinäre Endoskopie
Universitätsklinikum Eppendorf
Martinistr. 52
20251 Hamburg
Germany
m.anders@uke.uni-hamburg.de

PD Dr. Franz Georg Bader
Chirurgische Klinik und Poliklinik
Klinikum rechts der Isar
der Technischen Universität
Ismaninger Str. 22
81675 München
Germany
franz.bader@tum.de

Dr. Badma Bashankaev
National Research Center of Surgery
Department of Colorectal and Pelvic Floor Surgery
2 Abrikosovsky per.
119992 Moskau
Russia
badma.bashankaev@gmail.com

Prof. Dr. Jacques Belghiti
Hôpital Beaujon
Department of Surgery
100, Bd. Général Leclerc
92118 Clichy
France
jacques.belghiti@bjn.ap-hop-paris.fr

PD Dr. Andreas Bembenek
Klinik für Viszeralchirurgie
Krankenhaus Siloah
Klinikum Region Hannover
Roesebeckstr. 15
30449 Hannover
Germany
andreas.bembenek@krh.eu

Mariana Berho, M.D.
Professor of Medicine
Cleveland Clinic Florida
Department of Pathology
2950 Cleveland Clinic Boulevard
Weston FL 33331
USA
berhom@ccf.org

Prof. Dr. Dr. h.c.mult. Markus Büchler
Abteilung für Allgemeine, Viszerale und Transplantationschirurgie
Universitätsklinikum Heidelberg
Im Neuenheimer Feld 110
69120 Heidelberg
Germany
markus.buechler@med.uni-heidelberg.de

Prof. Dr. Heinz J. Buhr
Allgemein-, Gefäß- und Thoraxchirurgie
Charité Universitätsmedizin
Campus Benjamin Franklin (CBF)
Hindenburgdamm 30
12203 Berlin
Germany
heinz.buhr@charite.de

Prof. Sir John Burn
Institute of Genetic Medicine
Newcastle University
Central Parkway
Newcastle-upon Tyne NE13BZ
Great Britain
john.burn@ncl.ac.uk

Prof. Dr. Dr. h.c.mult. Meinhard Classen
Golfweg 11
6370 Reith b. Kitzbühel
Austria
meinhard.classen@lrz.tum.de

Prof. Dr. Pierre-Alain Clavien
Universitätsspital Zürich
Klinik für Viszeral- und Transplantationschirurgie
Rämistrasse 100
8091 Zürich
Switzerland
pierre-alain.clavien@usz.ch
Prof. Dr. P. Ronan O’Connell  
St. Vincent’s Hospital  
Department of Surgery  
Elm Park  
Dublin 4  
Ireland  
ronan.oconnell@ucd.ie

Philip B. Paty, M.D.  
Memorial Sloan-Kettering  
Cancer Center  
Department of Surgery  
Colorectal Service  
1275 York Avenue  
New York NY 10065  
USA  
patyp@mskcc.org

Prof. Dr. Aurel Perren  
Universität Bern  
Pathologisches Institut  
Murtenstraße 31  
3010 Bern  
Switzerland  
aurel.perren@pathology.unibe.ch

Prof. Dr. Phil Quirke  
St. James’s University Hospital  
Pathology and Tumour Biology  
Wellcome Trust Brenner Bldg.  
Beckett Street  
Leeds LS9 7TF  
Great Britain  
p.quirke@leeds.ac.uk

PD Dr. Dr. Uwe Johannes Roblick  
Klinik f. Allg. Chirurgie  
Universitätsklinikum Schleswig-Holstein, Campus Lübeck  
Ratzeburger Allee 160  
23562 Lübeck  
Germany  
drdr.ujroblick@me.com

Don C. Rockey, M.D.  
Professor of Medicine  
University of Texas  
Southwestern Medical Center  
Div. of Digestive & Liver Diseas  
5959 Harry Hines Boulevard  
Dallas TX 75390  
USA  
don.rockey@utsouthwestern.edu

Prof. Dr. Claus Rödel  
Klinik für Strahlentherapie und Onkologie  
Klinikum der Johann Wolfgang  
Goethe-Universität Frankfurt  
Theodor-Stern-Kai 7  
60596 Frankfurt  
Germany  
claus.roedel@kgu.de

Prof. Dr. Thomas Rösch  
Klinik und Poliklinik für  
Interdisziplinäre Endoskopie  
Universitätsklinikum Eppendorf  
Martinistr. 52  
20251 Hamburg  
Germany  
t.roesch@uke.de

Prof. Dr. Dr. Gerhard Rogler  
Universitätsspital Zürich  
Klinik für Gastroenterologie & Hepatologie  
Rämistrasse 100  
8091 Zürich  
Switzerland  
gerhard.rogler@usz.ch

Prof. Dr. Robert Rosenberg  
Kantonsspital Baden  
Klinik f. Allgemein-, Viszeral- und Gefäßchirurgie  
5404 Baden  
Switzerland  
robert.rosenberg@ksb.ch

Prof. Dr. Eric Rullier  
Hôpital Universitaire Saint André  
Department of Surgery  
1 Rue Jeau Burguel  
33075 Bordeaux Cedex  
France  
eric.rullier@chu-bordeaux.fr
Prof. Dr. Ramon Salazar
Institut Català d’Oncologia
IDIBELL
Gran Via s/n, Km 2.7
08907 L’Hospitalet, Barcelona
Spain
ramonsalazar@iconcologia.net

Dr. Brian Saunders
St. Mark’s Hospital
Wolfson Unit for Endoscopy
Watford Road
Harrow HA1 3UJ
Great Britain
b.saunders@imperial.ac.uk

Prof. Dr. Roland M. Schmid
II. Medizinische Klinik und Poliklinik
Klinikum rechts der Isar
der Technischen Universität
Ismaninger Str. 22
81675 München
Germany
roland.schmid@lrz.tum.de

Prof. Dr. Wolff Schmiegel
Medizinische Universitätsklinik
Ruhr-Universität Bochum
In der Schornau 23-25
44892 Bochum
Germany
wolff.schmiegel@ruhr-uni-bochum.de

Prof. Dr. Sabine Tejpar
Digestive Oncology Unit
University Ziekenhuis
Gasthuisberg
Herastraat 49
3000 Leuven
Belgium
sabine.tejpar@uz.kuleuven.ac.be

Prof. Dr. Emmanuel Tiret
Hôpital Saint Antoine
Service de Chirurgie Digestive
184, Rue du Faubourg St.-Antoine
75571 Paris
France
emmanuel.tiret@sat.aphp.fr

Prof. Dr. Albert Tuchmann
Krankenhaus Florisdorf
I. Chirurgische Abteilung
Hinaysgasde 1
1210 Wien
Austria
albert.tuchmann@wienkav.at

Prof. Dr. Eric van Cutsem
Division of Digestive Oncology
University of Leuven
Herastraat 49
3000 Leuven
Belgium
eric.vancutsem@med.kuleuven.be

Prof. Dr. Cornelis J.H. van de Velde
Academisch Ziekenhuis Leiden
Dep. of Surgery
Albinusdreef 2
2333 ZA Leiden
The Netherlands
c.j.h.van_de_velde@lumc.nl

PD Dr. Carsten T. Viehl
Universitätssspital Basel
Viszeralchirurgie
Spitalgasde 21
4031 Basel
Switzerland
cviehl@uhbs.ch

Dr. Klaus Weber
Chirurgische Klinik und Poliklinik
Universitätsklinikum
Erlangen-Nürnberg
Krankenhausstr. 12
91054 Erlangen
Germany
klaus.weber@uk-erlangen.de

Steven D. Wexner, M.D.
Professor of Medicine
Cleveland Clinic Florida
Department of Colorectal Surgery
2950 Cleveland Clinic Boulevard
Weston FL 33331
USA
wexners@ccf.org
**Congress Office**

**During** the V Falk Gastro-Conference

The Westin Grand Hotel
Arabellastr. 6
81925 Munich
Germany

Telephone: +49 (0) 175 / 77 95 327
Telefax: +49 (0) 89 / 92 64 92 01

**Opening Hours:**
- Tuesday, February 7, 2012 16.00 – 21.00 h
- Wednesday, February 8, 2012 7.30 – 18.00 h
- Thursday, February 9, 2012 8.00 – 18.10 h
- Friday, February 10, 2012 8.00 – 18.15 h
- Saturday, February 11, 2012 8.00 – 18.10 h

**Congress Fees**

Scientific program of the Falk Symposium 182

- € 200,-
- Students and residents
  - € 100,-

**Day ticket**

- € 120,-
- Students and residents
  - € 60,-

**The congress fees include:**
- Welcome Evening on February 7, 2012
- Refreshments during coffee breaks
- Lunch on February 10 and 11, 2012
- A copy of the abstract volume

**Admission to Scientific Events**

For admission to scientific events your name badge should be clearly visible.

**Congress Report**

The official congress report of the Falk Symposium 182 “Carcinogenesis, Prevention and Treatment of Colorectal Cancer – State-of-the-Art 2012” will be published in English in the second half of 2012 by Karger Publishers, Basel, Switzerland. Orders for this book at a reduced subscription price of € 35,- can be placed at the Congress Office during the congress in Munich.

**Congress Short Report**

The congress short report of the V Falk Gastro-Conference will be published by the Falk Foundation e.V. with number FSK 181-182 in the second half on 2012. Orders for this short report, free of charge, can be placed with the Falk Foundation e.V.
Innovative Drugs
for bowel and liver diseases
Modern formulations and specially designed delivery systems ensure targeted release of the active drug

Scientific Dialogue
in the interest of therapeutic progress
Falk Symposia and Workshops
nearly 250, attended by more than 100,000 participants from over 100 countries since 1967
Continuing medical education seminars
over 14,000, attended by more than one million physicians and patients in Germany alone
Comprehensive literature service for healthcare professionals and patients
with more than 200 publications
General Information:

FALK FOUNDATION e.V.
Leinenweberstr. 5
79108 Freiburg
Germany

Congress Division
Telephone: +49(0)761/1514-0
Telefax: +49(0)761/1514-359
E-mail: symposia@falkfoundation.de
www.falkfoundation.org